## 1 Introduction  
Around 70-90% of new drugs have poor water solubility, meaning that they do not work as well when taken orally [1]. Recent studies have shown that about 70% of new drugs have this issue, making it a major hurdle in drug development [2]. To address this, scientists have turned to a technique called drug amorphization. This method works because amorphous drugs, which are not in a crystal form, have higher free energy. This helps them to dissolve better in water and improves their effectiveness when taken orally [3]. However, the downside is that amorphous drugs often revert to crystals over time, especially during storage and when dissolving, due to their natural instability [4]. Non-covalent adaptable networks (NANs) come into play at this point. Also known as vitrimers, NANs use reversible non-covalent bonds that allow the network structure to adjust and recover without falling apart. Recent research by [PERSON] et al. (2022) shows that adding NANs to drug formulations can help prevent crystallization by keeping the drug in its amorphous state and reducing its instability [5]. Additionally, a study by [PERSON] et al. (2023) found that NANs are better at keeping amorphous drugs soluble compared to traditional methods due to their ability to avoid crystallization during storage [6]. Amorphous solid dispersion (ASD) is a widely used technique to improve the stability and effectiveness of drugs that do not dissolve easily by embedding them in a polymer matrix. The success of ASD depends on how well a drug interacts with a polymer to keep it in an amorphous (non-crystalline) state and prevent crystallization, which otherwise can reduce the drug's effectiveness [7]. Recently, there have been significant advancements in the integration of NANs into drug-polymer matrices. Moreover, NANs utilize strong but reversible non-covalent interactions, such as hydrogen bonding, electrostatic forces, and hydrophobic interactions. These networks allow the polymer matrix to adapt and maintain stability without the need for covalent changes [8]. By incorporating NANs, researchers can enhance the stabilization of amorphous drugs within ASDs, effectively preventing crystallization and ensuring that these drugs remain highly soluble throughout their storage and use. This approach leverages the dynamic adaptability of non-covalent interactions to improve drug efficacy and stability in pharmaceutical applications [9]. This innovative approach could greatly enhance the performance of ASD formulations by providing added stability and minimizing crystallization risks, leading to more effective treatments for drugs that are difficult to dissolve. Recent studies have suggested that NANs, employing non-covalent adaptable networks, not only enhance the stability of ASD formulations but also extend the shelf life of amorphous drugs by preventing their conversion into crystalline forms [10]. For example, research by [PERSON] and [PERSON] (2023) demonstrated that NANs can significantly reduce crystallization in drug formulations compared to traditional polymers, resulting in more reliable and effective drug delivery [11]. Furthermore, [PERSON] et al. (2023) highlighted the potential of NANs to improve the solubility and bioavailability of poorly soluble drugs, making them a promising addition to future pharmaceutical formulations [12]. Polymeric materials are frequently employed in the formulation of supersaturated amorphous drugs to prevent crystallization and maintain the high supersaturated solution [13]. However, there is a limited availability of methods for accurately predicting the correct selection of the most suitable polymer for preserving supersaturated drug solutions. The ability of polymers to inhibit nucleation and crystal growth is crucial for preventing crystallization and maintaining supersaturated drug solutions.